Clinical Trials
2 trialsNCT02998567 2026-05-12
HyPeR
Royal Marsden NHS Foundation Trust
Phase 1 Active not recruiting
NCT03220477 2025-08-06
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting